Keith F DeLuca, Jeanne E Mick ... Jennifer G DeLuca
Tools and methodologies to create and diversify recombinant antibodies and antibody fragments provide researchers with the ability to generate low-cost, high-yield immunological reagents.
Nicolas P Andrews, Justin X Boeckman ... James S Trimmer
This paper describes an effective pipeline for conversion of conventional monoclonal antibodies into recombinant form that results in an IgG subclass switch that greatly expands their utility for multiplex labeling.
Open science and consensus antibody validation protocols can identify high-quality, renewable antibodies for the ~50% of the human proteome currently covered, enabling robust and reproducible biomedical research.
Ching-Lin Hsieh, Christopher P Ptak ... Yung-Fu Chang
The antibody accessibility of the leptospiral surface protein, LigB, provides a guide for the rational design of improved recombinant chimeric vaccine antigens displayed on a single domain scaffold.
A strategy to identify high-quality commercially available antibodies for research reveals extensive use of non-specific antibodies and offers solutions for future large-scale testing.
Yiska Weisblum, Fabian Schmidt ... Paul D Bieniasz
SARS-CoV-2 spike variants that resist neutralization by therapeutic antibodies or convalescent plasma can be generated in the laboratory and exist at low frequency in natural populations.
Camila Tenorio França, Michael T White ... Ivo Mueller
Antibody responses to individual and optimal combinations of P. vivax recombinant proteins in naturally-exposed populations help to identify correlates of protective immunity, and establish a clear path to testing a multicomponent P. vivax vaccine.
By fusing influenza viral conserved epitopes and a superantigen fragment, we constructed a recombinant protein that might be a candidate universal broad-spectrum vaccine for the prevention and treatment of multiple influenza viruses.
Takashi Watanabe, Hikaru Hata ... Hidehiro Fukuyama
A Golden Gate-based dual-expression vector enables rapid screening, which facilitates efficient isolation of high-affinity cross-reactive antibodies for therapeutic or diagnostic use and provides a crucial advance for pandemic preparedness.
There is an ongoing need for researchers and all stakeholders to better understand issues surrounding antibody characterization to improve the quality and reproducibility of research that employs these reagents.
